Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02Lester J. Peters, Danny Rischin, Brian O’Sullivan et al.|Journal of Clinical Oncology|2010Cited by 806
Prognostic Significance of p16 <sup>INK4A</sup> and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III TrialDanny Rischin, Grant A. McArthur, Richard J. Young et al.|Journal of Clinical Oncology|2010Cited by 741
Prognostic Significance of [<sup>18</sup>F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02Danny Rischin, Lester J. Peters, Rodney J. Hicks et al.|Journal of Clinical Oncology|2006Cited by 543
Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology GroupDanny Rischin, Liz Kenny, Lester J. Peters et al.|Journal of Clinical Oncology|2010Cited by 372
The ‘QUAD SHOT’—a phase II study of palliative radiotherapy for incurable head and neck cancerJune Corry, Sandro Porceddu, Lester J. Peters et al.|Radiotherapy and Oncology|2005Cited by 258